Latest News

France’s Sanofi buys US hemophilia specialist Bioverativ

France-based drugmaker Sanofi is buying U.S. hemophilia specialist Bioverativ for $ 11.6 billion in a deal that Sanofi says will boost its profile for fighting rare diseases.
The Daily Star >> Live News

Leave a Reply

Your email address will not be published. Required fields are marked *

*